title: Haemodialysis of pyrazinamide in uraemic patients.
abstract: The pharmacokinetics of PZA during haemodialysis were determined in 6 patients with chronic renal impairment after a single oral dose of 25.7 (1.9) mg.kg-1. The dialysis clearance of PZA and of its metabolites were: pyrazinamide 132 ml.min-1; pyrazinoic acid 121 ml.min-1; 5-hydroxy-pyrazinamide 107 ml.min-1; 5-hydroxy-pyrazinoic acid 118 ml.min-1. The average amount extracted during a dialysis session of 4.1 h was 926 mg after an oral dose of 1700 mg. The high dialysability shows that PZA can properly be administered at the end of each dialysis session in the usual dose of 25 to 30 mg.kg-1.
authors.affiliation: Unités de Pharmacocinétique, Centre Hospitalier Général, Le Havre, France.
authors.forename: C
authors.initials: C
authors.lastname: Lacroix
authors.forename: A
authors.initials: A
authors.lastname: Hermelin
authors.forename: R
authors.initials: R
authors.lastname: Guiberteau
authors.forename: C
authors.initials: C
authors.lastname: Guyonnaud
authors.forename: J
authors.initials: J
authors.lastname: Nouveau
authors.forename: H
authors.initials: H
authors.lastname: Duwoos
authors.forename: O
authors.initials: O
authors.lastname: Lafont
mesh_terms: D000328:Adult; D001711:Biotransformation; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006801:Humans; D008297:Male; D011718:Pyrazinamide / Q000097:blood* / Q000378:metabolism / Q000493:pharmacokinetics; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood*
chemical_list: D011718:Pyrazinamide